Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical Developments
Alto Neuroscience Price Target Maintained With a $29.00/Share by Wedbush
Alto Neuroscience Analyst Ratings
Wedbush Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $29
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Analysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)
Wedbush Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $29
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $33
Buy Rating Affirmed for Alto Neuroscience, Inc. on Strong Clinical Trials and Strategic Precision Neuroscience Approach
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Optimistic Buy Rating for Alto Neuroscience Backed by Strategic Clinical Trials and Promising Data
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience Analyst Ratings
Rodman & Renshaw Initiates Coverage On Alto Neuroscience With Buy Rating, Announces Price Target of $43
Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment
TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience Analyst Ratings
Stifel Reiterates Buy on Alto Neuroscience, Maintains $32 Price Target